Watson Pharmaceuticals Inc Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals

Watson Pharmaceuticals Inc announced that it has sold its Rugby over-the-counter (OTC) pharmaceutical products and trademarks to The Harvard Drug Group, LLC, distributor and provider of private label OTCs and generic prescription products, for approximately $117 million. The transaction received clearance from the U.S. Federal Trade Commission on October 19, 2012 under requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). The Rugby OTC portfolio includes more than 250 SKUs of cough and cold, allergy, pain relief, nausea relief, nicotine gum, vitamin and nutritional supplement products which are sold through various healthcare outlets across the United States.